Project Details
Description
Study to Assess the Safety/Pharmacokinetics of Recomb Interleukin 21 (rIL-21) Admined Concomitantly w/Sorafenib (Nexavar) in Subjects w/Metastatic Renal Cell Carcinoma
Status | Finished |
---|---|
Effective start/end date | 7/1/07 → 12/31/11 |
Funding
- ZYMOGENITICS INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.